Table 4.
Overall survival in relation to standard clinicopathological prognostic factors and the studied markers
| Univariate analysis | Multivariate analysis | ||||||
|---|---|---|---|---|---|---|---|
| Predictive variables | CS | HR | CI | p | HR | CI | p |
| Age | |||||||
| <47 | 68% | 1 | 0.99, 1.02 | 0.880 | |||
| ≥ 47 * | 66% | ||||||
| Sex: | |||||||
| Male (42) | 59% | 1.1 | 0.85, 1.04 | 0.652 | |||
| Female (17) | 64% | ||||||
| Tumor type | |||||||
| SCC (27) | 60% | 1.212, | 0.538, 2.734 | 0.643 | |||
| TCC (27) | 65% | ||||||
| Adenocarcinoma (5) | 60% | ||||||
| Tumor grade | |||||||
| I (5) | 66% | 1.96 | 1.66, 21.331 | <0.000 | 4.350 | 1.786, 10.591 | 0.001 |
| II (39) | 32% | ||||||
| III (15) | 11% | ||||||
| Lymph Node Involvement: | 1.099 | 0.423, 2.859 | 0.846 | ||||
| Positive (10) | 49% | ||||||
| Negative (49) | 55% | ||||||
| Metastatic recurrence: | |||||||
| No (33) | 58% | 14.149 | 5.117, 39.123 | 0.000 | 14.903 | 5.315, 41.785 | 0.000 |
| Yes (21) | 25% | ||||||
| Pathological Stage: | |||||||
| p2 & pp3a (27) | 49% | 1.341 | 0.575, 3.127 | 0.498 | |||
| p3b &p4 (32) | 35% | ||||||
| Nm23 (IHC) | |||||||
| Positive (34) | 66.5% | 1.62 | 0.535, 2.244 | 0.345 | |||
| Negative (25) | 59.6% | ||||||
| nm23(RNA) | |||||||
| Positive (33) | 64.8% | 1.34 | 1.20, 1.50 | 0.021 | 0.695 | 0.586, 1.975 | 0.444 |
| Negative (19) | 35.5% | ||||||
| EGFR (IHC) | |||||||
| Positive (39) | 41% | 1.61 | 1.04, 2.29 | 0.034 | 3.576 | 1.206, 10.602 | 0.022 |
| Negative (20) | 69% | ||||||
| EGFR (RNA) | |||||||
| Positive (32) | 39% | 1.69 | 1.16, 2.74 | 0.031 | 3.911 | 1.148, 8.511 | 0.025 |
| Negative (20) | 69% | ||||||
| Rb | |||||||
| Positive (25) | 54% | 1.1 | 0.27, 1.76 | 0.287 | |||
| Negative (34) | 49% | ||||||
| p53 (IHC) | |||||||
| Positive (21) | 29% | 3.9 | 2.281, 12.42 | 0.011 | 2.512 | 0.948, 6.662 | 0.64 |
| Negative (38) | 60% | ||||||
| P53 (mutations) | |||||||
| Positive (8) | 0.539 | ||||||
| Negative (51) | |||||||
| Number of abnormal genes | 1.70 | 1.20, 5.90 | 0.022 | 7.331 | 2.696, 12.940 | 0.001 | |
| <2 | |||||||
| ≥ 2 | |||||||
* The median age for the studied patients
** Data regarding metastatic recurrence was available for 54 cases only